The fused BCR-ABL protein interacts with the interleukin 3beta(c) receptor subunit.
leukemia | Leukemia & Lymphoma Society | Leukemia | Chronic obstructive pulmonary disease | Acute lymphoblastic leukemia | Promyelocytic leukemia protein | chronic obstructive pulmonary disease | Chronic kidney disease | chronic kidney disease | Chronic fatigue syndrome | Acute myeloid leukemia | Suge Knight Represents: Chronic 2000 | Chronic traumatic encephalopathy | Chronic myelogenous leukemia | Chronic Kidney Disease | chronic fatigue syndrome | Chronic City | T-cell acute lymphoblastic leukemia | Feline leukemia virus | feline leukemia virus | Chronic toxicity | Chronic Town | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | chronic myelogenous leukemia | Chronic mountain sickness | Chronic inflammatory demyelinating polyneuropathy | Chronic bacterial prostatitis | Chronic | Cancer and Leukemia Group B |
Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March, 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.